NCT02880670已完成1 期
Pharmacokinetics and Metabolism of [14C] BMS-986142 in Healthy Male Subjects
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2016年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- The primary endpoint is PK parameters that will be determined from plasma concentration versus time
研究概览
简要总结
This is an open-label, single-dose, study in healthy males. The primary objective is to assess the pharmacokinetics (PK), metabolism, and routes of elimination of a single oral dose of radiolabeled BMS-986142 in healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Signed Informed Consent
- •Target population: Healthy males with no clinically significant deviations from normal in medical history, physical examinations, vital signs, electrocardiograms (ECGs), physical measurements, and clinical laboratory tests
- •Body weight of at least 50 kilograms (110 pounds); body mass index (BMI) between 18 to 32 kg/m2.
排除标准
- •History of any chronic or acute illness including active TB in the last 3 years, recent infection, gastrointestinal disease, smoking within less than 6 months prior to dosing, alcohol abuse, inability to tolerate oral medication, or inability to be venipunctured.
- •Vaccination or plans for vaccination with any live vaccine 12 weeks prior to first dose of study drug, during the course of the study, or 30 days after the last dose of study drug.
- •Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiograms, or clinical laboratory determinations beyond what is consistent with the target population.
- •History of allergies and adverse drug reaction to any oral contraceptive compounds or Bruton tyrosine kinase (BTK) inhibitors.
- •Participated in a radiolabeled drug study within the previous 12 months; clinically significant diagnostic or therapeutic radiation exposure within the previous 12 months; or current employment in a job requiring radiation exposure monitoring.
研究组 & 干预措施
Single dose of radiolabeled BMS-986142
Experimental
干预措施: BMS-986142 (Drug)
结局指标
主要结局
The primary endpoint is PK parameters that will be determined from plasma concentration versus time
时间窗: Day 1 to Day 13
Urinary/fecal/bile (if applicable) TRA (Total radioactivity) recovery data
时间窗: Day 1 to Day 13
次要结局
- Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, and the results of electrocardiogram tests (ECGs), vital signs, physical exams, and clinical laboratory tests.(Day 1 to Day 13)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of BMS-986195 in Healthy Male SubjectsRheumatoid ArthritisNCT03245515Bristol-Myers Squibb24
已完成
1 期
Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020Immunosuppression For DiseaseNCT02068053Bristol-Myers Squibb6
已完成
1 期
Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male SubjectsHealthyNCT01820806Galapagos NV6
已完成
1 期
Pharmacokinetics and Metabolism of (14C)-Labelled PXL770HealthyNCT03886103Poxel SA8
已完成
1 期
Pharmacokinetics and Metabolism Study in Healthy Male ParticipantsCancerNCT03247283Bristol-Myers Squibb9